Scott Power's love affair with Neuren continues despite not...

Scott Power's love affair with Neuren continues despite not having a coverage on the company:


ScoPo’s Powerplay – Neuren waiting on Phase 2 resultsMarket darling Neuren Pharmaceuticals (ASX:NEU) is again Power’s stock of the week with results from its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS) results scheduled for release this month.“The market is really focused on Neuren’s upcoming results given the size of the company and their importance,” Power says.Earlier this week NEU announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Pitt Hopkins syndrome has been completed, with initial results forecast by Q2 2024.Pitt Hopkins syndrome arises from alterations in the TCF4 gene and affects around 1 in 34,000 to 1 in 41,000 individuals, occasionally leading to an autism diagnosis.NEU is simultaneously conducting Phase 2 trials of NNZ-2591 for Angelman syndrome, and Prader-Willi syndrome. Each of these programs has received Orphan Drug designation from the US FDA and operates under Investigational New Drug (IND) applications.In March the USA FDA approved its compound trofinetide (now called DAYBUE) for Rett’s syndrome, the first drug for the treatment of the rare neurological disorder which emerges in infancy.Power says all of the syndromes present significant neurological challenges in early childhood, currently with few or no approved treatment options.